Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat Media Is Abbott's January Pullback a Good Time to Buy? Submitted by Thomas Hughes. First Published: 1/24/2026. 
Article Highlights - Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories (NYSE: ABT)'s January 2026 price pullback makes the stock look attractively valued. The move, driven more by market angst than by any fundamental weakness, appears to be a knee-jerk overreaction that has pushed the stock back into a buy zone. 
Some analysts are revisiting historical monetary resets and the role gold has played when governments faced large debt imbalances.
A new free report examines how gold was previously revalued to support national balance sheets, why recent comments from policymakers and investors have renewed interest in this topic, and what individuals may want to understand about protecting long-term savings during periods of monetary change. Download the free report here This zone aligns with market action from 2022–2024, when Abbott was recovering from its post–COVID-19 revenue contraction and institutional investors were actively accumulating the stock. Abbott Laboratories Growth Accelerates While some metrics in Abbott Laboratories' Q4 results and guidance missed expectations, revenue of $11.46 billion was up 4.5% year over year, margins improved, and adjusted earnings accelerated. Revenue growth trailed consensus by several hundred basis points, but margin strength helped offset the shortfall: adjusted earnings per share (EPS) rose about 12%, slightly above forecasts. By segment, results highlighted the strength of Abbott's diversified healthcare portfolio. Nutrition and Diagnostics contracted — Nutrition fell nearly 9% — but that weakness was offset by solid gains in Established Pharmaceuticals and Med Tech. Established Pharmaceuticals grew roughly 9%, driven by generics and expansion in emerging markets, while Med Tech advanced about 12.3% with broad-based strength across subsegments. Margin performance was encouraging even if it fell short of some analyst projections. A favorable product mix, strong Med Tech results, lower COVID-19-related sales and operational improvements pushed margins ahead of expectations. Management expects earnings to improve another ~10% in 2026, outpacing revenue growth and supporting its capital-return plans. Capital returns are a key part of the investment case. Abbott is a Dividend King, having raised its dividend annually for more than 50 years, and it appears positioned to continue doing so. After the pullback the stock yields roughly 2.5%, and the company is paying out under half of earnings, leaving cash flow available for share buybacks — an important offset to dilutive share-based compensation. Analysts Point to Robust Rebound in Abbott Laboratories Stock Some analysts noted the revenue miss, but there were no major rating or target changes on the morning of the earnings release. The prevailing view is that this is a fundamentally healthy company that can continue returning capital while reinvesting in growth. The consensus share price target reported by MarketBeat implies upside of as much as 30%, potentially putting the stock back toward all-time highs; even low-end targets imply some positive return potential. Key catalysts include an expanding Med Tech portfolio, integration of AI across operations and products, improving margins and strategic acquisitions. The announced deal for Exact Sciences is one example of an acquisition that could broaden Abbott's revenue and pipeline. That said, the pullback has been significant and could deepen. Institutional investors were net buyers through 2025 and may be buyers again at discounted prices. Early indications show tentative support in the $105–$110 range, but that level is not yet confirmed. A downside case could push shares to the low end of the buy zone — potentially near $95 or below — before a durable rebound.
| 
